Gland Pharma shareholders approved the company’s standalone and consolidated financial statements for FY26 at its 48th annual general meeting held on August 25, 2026. The assembly also endorsed the final dividend declaration for the fiscal year ended March 31, 2026.

The meeting, conducted via video conferencing, saw all five ordinary resolutions pass with requisite majorities. Voting was conducted through remote e-voting facilities provided by National Securities Depository Limited (NSDL), with no votes cast during the live session.

Director Reappointments Face Institutional Opposition

Shareholders approved the reappointment of Mr. Wenjie Zhang and Ms. Wei Huang as directors liable to retire by rotation. While both resolutions passed overall, they faced significant opposition from the public-institutional category.

Promoter and promoter group shares voted unanimously in favour of both directorships. However, public-institutional investors voted against Mr. Zhang’s reappointment by 44.84% and Ms. Huang’s by 46.64%. Public non-institutional shareholders supported both candidates with over 99% approval.

Financial Statements and Dividend Approved

The adoption of the audited standalone and consolidated financial statements for FY26 received near-unanimous support. Out of 143,340,164 votes polled, 143,340,154 were cast in favour, with only 10 votes against.

Similarly, the resolution to declare the final dividend on equity shares for FY26 passed with overwhelming backing. Of the 143,693,898 votes cast, 143,693,888 supported the measure.

What the Numbers Show

The voting data reveals a sharp divergence in shareholder sentiment regarding board composition versus financial oversight. While institutional investors showed negligible dissent on financial statements (0% against), nearly half of their votes opposed the reappointment of the two directors. This suggests specific governance concerns among large public holders that did not extend to the company’s reported financial performance or dividend policy.

Gland Pharma delivered a robust financial performance for the fiscal year ended March 2026, reporting a consolidated revenue of ₹64,307 million and a net profit after tax (PAT) of ₹10,273 million. The results reflect a year of meaningful margin expansion and operational efficiency across its global sterile injectable manufacturing business.

The company held its 48th Annual General Meeting on August 25, 2026, where Executive Chairman Srinivas Sadu outlined the strategic progress made during FY26. Shareholders approved the audited standalone and consolidated financial statements, along with the declaration of a final dividend. The meeting was conducted via video conferencing, complying with SEBI regulations.

Financial Performance Highlights

Gland Pharma’s top-line growth was supported by strong demand in key regulated markets, particularly the US and Europe. The company achieved an EBITDA of ₹16,295 million, representing a margin of 25%, which marks a significant improvement from the previous year.

Other income also saw substantial growth, rising 48% year-on-year to ₹3,163 million, contributing to a total income increase of 16% to ₹67,470 million.

Regional Growth Drivers

The US market remained the primary growth engine, contributing ₹34,214 million in revenue, up 13% from the previous year. This performance was bolstered by the launch of 31 new molecules, reinforcing the company’s market leadership in North America.

Europe recorded the highest growth rate among major regions, with revenue jumping 34% to ₹14,035 million. Other core markets, including Canada, Australia, and New Zealand, grew by 12% to ₹2,269 million. The Rest of the World segment contributed ₹11,117 million, while domestic operations in India generated ₹2,672 million.

Cenexi Turnaround

A key highlight of the fiscal year was the decisive turnaround at Cenexi, the company’s European subsidiary. Cenexi revenues grew by 25% to ₹18,693 million (€182 million). More importantly, operational efficiencies led to a significant improvement in EBITDA, narrowing the loss to ₹336 million (€3 million) compared to a loss of ₹1,761 million (€19 million) in FY25. The EBITDA margin improved from -12% to -2%.

What the Numbers Show

The divergence between revenue growth (14%) and PAT growth (47%) underscores the impact of operational leverage and cost discipline. With gross profit margins expanding from 63% to 65%, the company successfully translated higher volumes into disproportionately higher bottom-line profits. Additionally, the sharp reduction in Cenexi’s losses indicates that integration efforts are beginning to yield tangible financial benefits, reducing drag on consolidated earnings.

Strategic Outlook and ESG

Looking ahead, Gland Pharma is focusing on six strategic levers, including strengthening its Contract Development and Manufacturing Organization (CDMO) capabilities, expanding its complex injectables portfolio, and leveraging Cenexi as a platform for European growth. The company continues to invest in R&D, spending ₹2,230 million during the year, and has filed 24 new Abbreviated New Drug Applications (ANDAs).

On the sustainability front, the company reported conserving 5.79% in energy and recycling 51.03% of its water usage. It also executed 21 Corporate Social Responsibility (CSR) projects, benefiting over 61,000 individuals, aligning with United Nations Sustainable Development Goals.